FDG

Oncternal Therapeutics Provides Business Update and Announces Fourth Quarter and Full Year 2023 Financial Results

Retrieved on: 
Thursday, March 7, 2024

Our grant revenue was $0.3 million for the fourth quarter ended December 31, 2023 and was $0.8 million for the full year 2023.

Key Points: 
  • Our grant revenue was $0.3 million for the fourth quarter ended December 31, 2023 and was $0.8 million for the full year 2023.
  • Our total operating expenses for the fourth quarter ended December 31, 2023 were $9.9 million, including $2.2 million in non-cash stock-based compensation expense.
  • Research and development expenses for the quarter totaled $6.7 million, and general and administrative expenses for the quarter totaled $3.3 million.
  • We believe these funds will be sufficient to fund our operations into the first quarter of 2025.

Oncternal Therapeutics Updates the Status of its Phase 1/2 Study of ONCT-808, a ROR1-Targeting Autologous CAR T, in Patients with Relapsed or Refractory Aggressive B-cell Lymphoma

Retrieved on: 
Tuesday, December 26, 2023

No evidence of his lymphoma was found histologically, based on the patient’s initial autopsy report.

Key Points: 
  • No evidence of his lymphoma was found histologically, based on the patient’s initial autopsy report.
  • Salim Yazji M.D., Chief Medical Officer at Oncternal Therapeutics, commented, "The safety of every patient who participates in our studies is of the utmost priority for us.
  • We believe these early disease response data indicate that ONCT-808 is a particularly potent autologous CAR T product with the potential to address significant unmet needs for patients with aggressive B-cell malignancies.
  • With this clear path forward, we plan to implement the protocol amendment as rapidly as possible."

TransCode Therapeutics Reports Third Quarter 2023 Results; Provides Business Update

Retrieved on: 
Tuesday, November 14, 2023

BOSTON, Nov. 14, 2023 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ), the RNA oncology company committed to more effectively treating cancer using RNA therapeutics, today reported financial results for the third quarter ended September 30, 2023, and recent business progress.

Key Points: 
  • BOSTON, Nov. 14, 2023 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ), the RNA oncology company committed to more effectively treating cancer using RNA therapeutics, today reported financial results for the third quarter ended September 30, 2023, and recent business progress.
  • TransCode co-founder and Chief Technology Officer, Dr. Zdravka Medarova, commented, “We also announced encouraging preclinical data in glioblastoma multiforme (GBM) with our lead candidate.
  • Research and development expense was approximately $3.3 million in the third quarter of 2023, compared to approximately $3.0 million in the third quarter of 2022.
  • General and administrative expense was approximately $2.0 million in the third quarter of 2023, compared to approximately $1.9 million in the third quarter of 2022.

RefleXion Announces Initial Close of $105M Fundraising to Commercialize New Cancer Treatment

Retrieved on: 
Wednesday, November 15, 2023

These new funds will allow RefleXion to extend commercialization of its breakthrough SCINTIX® therapy for treating all stages of indicated solid tumor cancers, including metastatic disease.

Key Points: 
  • These new funds will allow RefleXion to extend commercialization of its breakthrough SCINTIX® therapy for treating all stages of indicated solid tumor cancers, including metastatic disease.
  • “TPG’s support has been foundational in our journey, and we are gratified that they are leading a significant investment in RefleXion.
  • “We are delighted to see RefleXion reach a stage where they can accelerate their impact and deliver treatment and outcomes at scale.
  • The RefleXion X1 is also cleared for image-guided external-beam radiotherapy for solid tumors located anywhere in the body.

Per-Encounter Medical Market to Hit $327.84 Billion, Globally, by 2030 at 16% CAGR: Coherent Market Insights

Retrieved on: 
Thursday, December 7, 2023

The Per-Encounter Medical Market is influenced by various factors that drive its growth and reshape its landscape.

Key Points: 
  • The Per-Encounter Medical Market is influenced by various factors that drive its growth and reshape its landscape.
  • Request Sample Copy of this Report: https://www.coherentmarketinsights.com/insight/request-sample/6386
    Another driver boosting the growth of the Per-Encounter Medical Market is the demand for personalized healthcare services.
  • Per-encounter medical services enable healthcare providers to deliver personalized care by facilitating a one-on-one relationship between the patient and the healthcare professional.
  • Read complete market research report," Per-Encounter Medical Market, By Product Type, By Application, By Distribution Channel, By Region, and Segment Forecast 2023-2030 ", Published by Coherent Market Insights.

Per-Encounter Medical Market to Hit $327.84 Billion, Globally, by 2030 at 16% CAGR: Coherent Market Insights

Retrieved on: 
Thursday, December 7, 2023

The Per-Encounter Medical Market is influenced by various factors that drive its growth and reshape its landscape.

Key Points: 
  • The Per-Encounter Medical Market is influenced by various factors that drive its growth and reshape its landscape.
  • Request Sample Copy of this Report: https://www.coherentmarketinsights.com/insight/request-sample/6386
    Another driver boosting the growth of the Per-Encounter Medical Market is the demand for personalized healthcare services.
  • Per-encounter medical services enable healthcare providers to deliver personalized care by facilitating a one-on-one relationship between the patient and the healthcare professional.
  • Read complete market research report," Per-Encounter Medical Market, By Product Type, By Application, By Distribution Channel, By Region, and Segment Forecast 2023-2030 ", Published by Coherent Market Insights.

TransCode Therapeutics Announces Preliminary Clinical Results in First Patient in Phase 0 Clinical Study with Lead Therapeutic Candidate, TTX-MC138

Retrieved on: 
Tuesday, October 24, 2023

In addition, radiolabeled TTX-MC138 had pharmacokinetic behavior consistent with that expected based on non-clinical IND-enabling studies.

Key Points: 
  • In addition, radiolabeled TTX-MC138 had pharmacokinetic behavior consistent with that expected based on non-clinical IND-enabling studies.
  • Complete analysis of data from this first patient is in process and will be included in the final report for all patients enrolled in the study.
  • The trial is intended to yield important data regarding TTX-MC138 delivery to clinical metastases that could inform dose selection and frequency, for further clinical development.
  • “Our Phase 0 trial involves a single microdose of radiolabeled TTX-MC138 followed by noninvasive PET-MRI imaging and metabolite analysis.

BRUKINSA® Receives Positive Recommendation from NICE in U.K. for Adult Patients with Chronic Lymphocytic Leukemia

Retrieved on: 
Friday, October 20, 2023

“This follows the previous approval of BRUKINSA by NICE in July 2022 as the only cost-effective treatment for patients with Waldenstrom’s macroglobulinemia.

Key Points: 
  • “This follows the previous approval of BRUKINSA by NICE in July 2022 as the only cost-effective treatment for patients with Waldenstrom’s macroglobulinemia.
  • “This decision represents a significant milestone for patients in England and Wales with CLL, the most common form of leukemia in adults,” said Nick York, Patient Advocacy Healthcare Liaison Officer, U.K. Leukemia Care.
  • “Despite continued treatment advances, many patients with CLL will relapse and need additional treatment options.
  • Furthermore, a proportion of patients have a disease which is refractory to initial treatment.”
    BRUKINSA is the third BTKi for CLL to be recommended by NICE for routine commissioning.

RefleXion Showcases Breakthrough SCINTIX Biology-Guided Radiotherapy and Highlights New Research at ASTRO 2023 Meeting

Retrieved on: 
Thursday, September 28, 2023

RefleXion® Medical , a therapeutic oncology company, today announced the company will showcase the RefleXion® X1 with SCINTIX™ biology-guided radiotherapy at the American Society for Radiation Oncology ( ASTRO ) Annual Meeting, Oct. 1-4, 2023 in San Diego (booth #2831).

Key Points: 
  • RefleXion® Medical , a therapeutic oncology company, today announced the company will showcase the RefleXion® X1 with SCINTIX™ biology-guided radiotherapy at the American Society for Radiation Oncology ( ASTRO ) Annual Meeting, Oct. 1-4, 2023 in San Diego (booth #2831).
  • “Highlights from these presentations explore critical aspects of X1 performance in dosimetric accuracy, workflow, FDG uptake, and exquisite kVCT image quality.
  • The following oral and panel presentations highlight some of the new research being presented at ASTRO 2023.
  • The RefleXion booth will also feature a multi-target SCINTIX technology interactive demonstration and SCINTIX treatment planning demonstrations.

City of Hope is the first cancer center in Southern California to offer patients novel targeted radiotherapy

Retrieved on: 
Monday, August 28, 2023

LOS ANGELES, Aug. 28, 2023 /PRNewswire/ -- City of Hope, one of the largest cancer research and treatment organizations in the United States, is the first health system in Southern California to offer patients diagnosed with primary or metastatic lung and bone cancer a new form of radiotherapy that can detect and treat multiple tumors in real time using precision targeting.

Key Points: 
  • The RefleXion® X1 system delivers SCINTIXTM biology-guided radiotherapy, a leading-edge treatment that combines positron emission tomography (PET) with targeted radiation therapy.
  • As part of their treatment regimen, between half and two-thirds of cancer patients receive radiotherapy, according to the American Society for Therapeutic Radiology and Oncology.
  • Through their efforts, City of Hope researchers hope to bring the world closer to the ability to deliver personalized radiotherapy treatment that is specific to a particular cancer.
  • City of Hope is a minority investor in RefleXion, and currently holds less than 1% of the company's outstanding shares.